CAMBRIDGE, Mass. – May 29, 2020 – Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the promotion of Alan Collis, Ph.D., to Senior Vice President, Preclinical Development.

“Alan’s leadership has been integral to the robust progress of Nimbus’ pipeline in recent years, including the successful completion of preclinical development of our Tyk2 allosteric inhibitor, and the generation of promising preclinical data from our HPK1 program, which will be showcased at the AACR Virtual Annual Meeting next month,” said Peter J. Tummino, Ph.D., Chief Scientific Officer of Nimbus. “Additionally, Nimbus will soon be announcing new preclinical programs for a number of valuable targets, and we’re excited that this expanded pipeline will continue to benefit from Alan’s broad expertise and leadership.”

“Nimbus’ success is a product not just of our structure-based drug discovery platform, but the powerful combination of that technology with our team’s deep expertise in biopharmaceutical drug development. Alan’s impact at Nimbus perfectly reflects the two successfully coming together,” said Annie C. Chen, M.D., MPH, Chief Medical Officer of Nimbus and President of the company’s Tyk2 subsidiary, Nimbus Lakshmi, Inc. “We heartily congratulate him on this well-deserved promotion.”

Dr. Collis joined Nimbus in 2018 to lead the company’s Tyk2 program, and was appointed Vice President, Preclinical Development, in early 2019. Prior to joining Nimbus, he was Executive Director of DMPK at Forma Therapeutics, in which role he transitioned two projects into Phase II, four through IND, and five through preclinical profiling. Before that, Dr. Collis served as Novartis’ Executive Director of Scientific and Strategic Planning and Global Leader of the Metabolism and Pharmacokinetics group. In that role, he advised on all aspects of project strategy, compound progression, and business planning. Earlier in his career, Dr. Collis held significant leadership roles in medicinal chemistry in the large pharma settings of Aventis, Rhone-Poulenc Rorer, and Pfizer.

About Nimbus Therapeutics

Nimbus Therapeutics designs breakthrough medicines. Utilizing its powerful structure-based drug discovery engine, Nimbus designs potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. The company’s LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. Nimbus is headquartered in Cambridge, Mass. www.nimbustx.com

Media Contact

Lisa Raffensperger, (617) 903-8783
Ten Bridge Communications
lisa@tenbridgecommunications.com

DOWNLOAD PRESS RELEASE